BNR

Burning Rock Biotech

19.12 USD
+1.07
5.93%
At close Updated Mar 20, 4:00 PM EDT
1 day
5.93%
5 days
12.87%
1 month
-34.09%
3 months
-18.26%
6 months
111.97%
Year to date
-2.85%
1 year
231.94%
5 years
-92.46%
10 years
-92.24%
 

About: Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.

Employees: 674

0
Funds holding %
of 8,088 funds
Analysts bullish %
Positive news %
Price charts implemented using Lightweight Charts™